Laboratory medicine for molecular imaging of atherosclerosis

Clinica Chimica Acta

Volumn 437, Issue , 2014, Pages 19-24

  Mangge, Harald ^a,b   Almer, Gunter ^a   Stelzer, Ingeborg ^a   Reininghaus, Eva ^a   Prassl, Ruth ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b BIOTECHMED GRAZ   (Austria)

Author keywords

Laboratory medicine; Molecular imaging of atherosclerosis; Nanotechnology

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; CYTOKINE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 19; INTERLEUKIN 27; INTERLEUKIN 35; INTERLEUKIN 37; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; NANOPARTICLE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CEREBROVASCULAR ACCIDENT; CYTOKINE RESPONSE; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; DISEASE SEVERITY; HEART INFARCTION; HUMAN; IMMUNOMODULATION; INFECTION; INFLAMMATION; MOLECULAR IMAGING; NANOMEDICINE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VASCULITIS; ANIMAL; IMMUNOLOGY; METABOLISM; PLAQUE, ATHEROSCLEROTIC; PROCEDURES; TRENDS;

ANIMALS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; MOLECULAR IMAGING; PLAQUE, ATHEROSCLEROTIC;

EID: 84904468515     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.06.029     Document Type: Review

References (125)

1. Rocha V.Z., Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009, 6:399-409.
2. Mallat Z., Taleb S., Ait-Oufella H., Tedgui A. The role of adaptive T cell immunity in atherosclerosis. J Lipid Res 2009, 50:S364-S369. [Suppl.].
3. Ait-Oufella H., Taleb S., Mallat Z., Tedgui A. Cytokine network and T cell immunity in atherosclerosis. Semin Immunopathol 2009, 31:23-33.
4. Ait-Oufella H., Taleb S., Mallat Z., Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 2011, 31:969-979.
5. Mangge H., Almer G., Truschnig-Wilders M., Schmidt A., Gasser R., Fuchs D. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem 2010, 17:4511-4520.
6. Salagianni M., Galani I.E., Lundberg A.M., et al. Toll-like receptor 7 protects from atherosclerosis by constraining "inflammatory" macrophage activation. Circulation 2012, 126:952-962.
7. Sanz J., Fayad Z.A. Imaging of atherosclerotic cardiovascular disease. Nature 2008, 451:953-957.
8. Helft G., Worthley S.G., Fuster V., et al. Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging. Circulation 2002, 105:993-998.
9. Camici P.G., Rimoldi O.E., Gaemperli O., Libby P. Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur Heart J 2012, 33:1309-1317.
10. Mulder W.J., Strijkers G.J., van Tilborg G.A., Cormode D.P., Fayad Z.A., Nicolay K. Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res 2009, 42:904-914.
11. Lobatto M.E., Fuster V., Fayad Z.A., Mulder W.J. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov 2011, 10:835-852.
12. Kumar R., Ohulchanskyy T.Y., Turowski S.G., Thompson M.E., Seshadri M., Prasad P.N. Combined magnetic resonance and optical imaging of head and neck tumor xenografts using Gadolinium-labelled phosphorescent polymeric nanomicelles. Head Neck Oncol 2010, 2:35.
13. Frascione D., Diwoky C., Almer G., et al. Ultrasmall superparamagnetic iron oxide (USPIO)-based liposomes as magnetic resonance imaging probes. Int J Nanomedicine 2012, 7:2349-2359.
14. Heuer-Jungemann A., Harimech P.K., Brown T., Kanaras A.G. Gold nanoparticles and fluorescently-labelled DNA as a platform for biological sensing. Nanoscale 2013, 5:9503-9510.
15. 18F]YF3 nanoparticles for PET imaging. Nanoscale 2013, 5:3253-3256.
16. Zhao Y., Sultan D., Detering L., et al. Copper-64-alloyed gold nanoparticles for cancer imaging: improved radiolabel stability and diagnostic accuracy. Angew Chem Int Ed Engl 2014, 53:156-159.
17. 89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. Bioconjug Chem 2011, 22:2383-2389.
18. Ghanem G.E., Joubran C., Arnould R., Lejeune F., Fruhling J. Labelled polycyanoacrylate nanoparticles for human in vivo use. Appl Radiat Isot 1993, 44:1219-1224.
19. Zhang Y., Wang T.H. Quantum dot enabled molecular sensing and diagnostics. Theranostics 2012, 2:631-654.
20. Go A.S., Mozaffarian D., Roger V.L., et al. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:143-152.
21. Naghavi M., Falk E., Hecht H.S., et al. From vulnerable plaque to vulnerable patient-Part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol 2006, 98:2H-15H.
22. Bertocchi C., Traunwieser M., Dorler J., Hasslacher J., Joannidis M., Dunzendorfer S. Atorvastatin inhibits functional expression of proatherogenic TLR2 in arterial endothelial cells. Cell Physiol Biochem 2011, 28:625-630.
23. Schiopu A., Cotoi O.S. S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease. Mediators Inflamm 2013, 2013:828354.
24. Chiu J.J., Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 2011, 91:327-387.
25. Gleissner C.A. Macrophage phenotype modulation by CXCL4 in atherosclerosis. Front Physiol 2012, 3:1.
26. Fenyo I.M., Gafencu A.V. The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis. Immunobiology 2013, 218:1376-1384.
27. Dietel B., Cicha I., Voskens C.J., Verhoeven E., Achenbach S., Garlichs C.D. Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells. Atherosclerosis 2013, 230:92-99.
28. Tabas I., Williams K.J., Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
29. Badimon L., Martinez-Gonzalez J., Llorente-Cortes V., Rodriguez C., Padro T. Cell biology and lipoproteins in atherosclerosis. Curr Mol Med 2006, 6:439-456.
30. Willems S., Vink A., Bot I., et al. Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. Eur Heart J 2013, 34:3699-3706.
31. Ramalho L.S., Oliveira L.F., Cavellani C.L., et al. Role of mast cell chymase and tryptase in the progression of atherosclerosis: study in 44 autopsied cases. Ann Diagn Pathol 2013, 17:28-31.
32. Kolodgie F.D., Narula J., Yuan C., Burke A.P., Finn A.V., Virmani R. Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy?. J Am Coll Cardiol 2007, 49:2093-2101.
33. Quercioli A., Montecucco F., Bertolotto M., et al. Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling. Eur J Clin Invest 2010, 40:645-654.
34. Mauriello A., Servadei F., Zoccai G.B., et al. Coronary calcification identifies the vulnerable patient rather than the vulnerable Plaque. Atherosclerosis 2013, 229:124-129.
35. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012, 32:2045-2051.
36. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
37. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003, 108:1772-1778.
38. Springall R., Amezcua-Guerra L.M., Gonzalez-Pacheco H., et al. Interferon-gamma increases the ratio of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in peripheral monocytes from patients with coronary artery disease. PLoS One 2013, 8:e72291.
39. Jeerakathil T., Lo W. Infection as cause of stroke: a contagious idea that may explain racial disparity. Neurology 2014, 82:908-909.
40. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
41. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44.
42. Mauriello A., Sangiorgi G., Fratoni S., et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 2005, 45:1585-1593.
43. van Wijk D.F., Boekholdt S.M., Wareham N.J., et al. C-reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the prospective EPIC-Norfolk cohort study. Arterioscler Thromb Vasc Biol 2013, 33:2888-2894.
44. Galimudi R.K., Spurthi M.K., Padala C., et al. Interleukin 6(-174G/C) variant and its circulating levels in coronary artery disease patients and their first degree relatives. Inflammation 2013, 37:314-321.
45. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136-2142.
46. Duivenvoorden R., Mani V., Woodward M., et al. Relationship of Serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: The dal-PLAQUE Study. JACC Cardiovasc Imaging 2013, 6:1087-1094.
47. Thompson A., Gao P., Orfei L., et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544.
48. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998, 351:88-92.
49. Ragino Y.I., Chernyavskiy A.M., Tsimbal S.Y., Shcherbakova L.V., Polonskaya Y.V., Kashtanova E.V. Relationship of blood levels of inflammatory and destructive biomarkers in coronary atherosclerosis with long-term results of surgical revascularization. Bull Exp Biol Med 2013, 155:314-317.
50. Tretjakovs P., Jurka A., Bormane I., et al. Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina. Clin Chim Acta 2012, 413:25-29.
51. Perek B., Malinska A., Misterski M., et al. Preexisting high expression of matrix metalloproteinase-2 in tunica media of saphenous vein conduits is associated with unfavorable long-term outcomes after coronary artery bypass grafting. Biomed Res Int 2013, 2013:730721.
52. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol 2013, 168:5126-5134.
53. Zhang Z., Machac J., Helft G., et al. Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl Med 2006, 6:3.
54. 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006, 48:1818-1824.
55. 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am Heart J 2011, 162:214-221. [e212].
56. Mani V., Woodward M., Samber D., et al. Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study. Int J Cardiovasc Imaging 2014, 30:571-582.
57. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
58. Williams K.J., Tabas I. Lipoprotein retention-and clues for atheroma regression. Arterioscler Thromb Vasc Biol 2005, 25:1536-1540.
59. Frias J.C., Lipinski M.J., Lipinski S.E., Albelda M.T. Modified lipoproteins as contrast agents for imaging of atherosclerosis. Contrast Media Mol Imaging 2007, 2:16-23.
60. Cormode D.P., Skajaa T., Fayad Z.A., Mulder W.J. Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol 2009, 29:992-1000.
61. Allijn I.E., Leong W., Tang J., et al. Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level. ACS Nano 2013, 7:9761-9770.
62. Lipinski M.J., Amirbekian V., Frias J.C., et al. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med 2006, 56:601-610.
63. Mackness M., Durrington P., Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004, 15:399-404.
64. Grundy S.M., Balady G.J., Criqui M.H., et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998, 97:1876-1887.
65. Rosenson R.S., Brewer H.B., Chapman M.J., et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011, 57:392-410.
66. Ng K.K., Lovell J.F., Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res 2011, 44:1105-1113.
67. Liu X., Suo R., Xiong S.L., Zhang Q.H., Yi G.H. HDL drug carriers for targeted therapy. Clin Chim Acta 2013, 415:94-100.
68. Duivenvoorden R., Tang J., Cormode D.P., et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun 2014, 5:3065.
69. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
70. Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
71. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
72. Mangge H., Almer G., Haj-Yahya S., et al. Nuchal thickness of subcutaneous adipose tissue is tightly associated with an increased LMW/total adiponectin ratio in obese juveniles. Atherosclerosis 2009, 203:277-283.
73. Mangge H., Almer G., Haj-Yahya S., et al. Preatherosclerosis and adiponectin subfractions in obese adolescents. Obesity 2008, 16:2578-2584.
74. Bobbert T., Rochlitz H., Wegewitz U., et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 2005, 54:2712-2719.
75. van Stijn C.M., Kim J., Barish G.D., Tietge U.J., Tangirala R.K. Adiponectin expression protects against angiotensin ii-mediated inflammation and accelerated atherosclerosis. PLoS One 2014, 9:e86404.
76. Luo N., Liu J., Chung B.H., et al. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes 2010, 59:791-799.
77. Pilz S., Horejsi R., Moller R., et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J Clin Endocrinol Metab 2005, 90:4792-4796.
78. Pilz S., Maerz W., Weihrauch G., et al. Adiponectin serum concentrations in men with coronary artery disease: the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study. Clin Chim Acta 2006, 364:251-255.
79. Ouchi N., Ohishi M., Kihara S., et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42:231-234.
80. Shimabukuro M., Higa N., Asahi T., et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003, 88:3236-3240.
81. Waki H., Yamauchi T., Kamon J., et al. Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 2005, 146:790-796.
82. Fruebis J., Tsao T.S., Javorschi S., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001, 98:2005-2010.
83. Bruce C.R., Mertz V.A., Heigenhauser G.J., Dyck D.J. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes 2005, 54:3154-3160.
84. Palanivel R., Fang X., Park M., et al. Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. Cardiovasc Res 2007, 75:148-157.
85. Sun Y., Xun K., Wang C., et al. Adiponectin, an unlocking adipocytokine. Cardiovasc Ther 2009, 27:59-75.
86. Sun Y, Chen X. Effect of adiponectin on apoptosis: proapoptosis or antiapoptosis? Biofactors 36:179-186.
87. Pilz S., Mangge H., Wellnitz B., et al. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 2006, 91:4277-4286.
88. Almer G., Saba-Lepek M., Haj-Yahya S., et al. Globular domain of adiponectin: promising target molecule for detection of atherosclerotic lesions. Biologics Targets Ther 2011, 5:95-105.
89. Almer G., Wernig K., Saba-Lepek M., et al. Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques. Int J Nanomedicine 2011, 6:1279-1290.
90. Junghans M., Kreuter J., Zimmer A. Antisense delivery using protamine-oligonucleotide particles. Nucleic Acids Res 2000, 28:E45.
91. Lochmann D., Weyermann J., Georgens C., Prassl R., Zimmer A. Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization. Eur J Pharm Biopharm 2005, 59:419-429.
92. Weyermann J., Lochmann D., Georgens C., Zimmer A. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect. Eur J Pharm Biopharm 2005, 59:431-438.
93. Wernig K., Griesbacher M., Andreae F., et al. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles. J Control Release 2008, 130:192-198.
94. Packard R.R., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
95. Smedbakken L.M., Halvorsen B., Daissormont I., et al. Increased levels of the homeostatic chemokine CXCL13 in human atherosclerosis - potential role in plaque stabilization. Atherosclerosis 2012, 224:266-273.
96. Signorelli S.S., Anzaldi M., Fiore V., et al. Patients with unrecognized peripheral arterial disease (PAD) assessed by ankle-brachial index (ABI) present a defined profile of proinflammatory markers compared to healthy subjects. Cytokine 2012, 59:294-298.
97. Di Taranto M.D., Morgante A., Bracale U.M., et al. Altered expression of inflammation-related genes in human carotid atherosclerotic plaques. Atherosclerosis 2012, 220:93-101.
98. Schuett H., Oestreich R., Waetzig G.H., et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2012, 32:281-290.
99. Butcher M., Galkina E. Current views on the functions of interleukin-17A-producing cells in atherosclerosis. Thromb Haemost 2011, 106:787-795.
100. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Llorca J., Castaneda S. The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritis: comment on 'Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review' by Jamnistki et al. Ann Rheum Dis 2014, 73(5):e27. 10.1136/annrheumdis-2013-205154.
101. Papagoras C., Voulgari P.V., Drosos A.A. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 2013, 31:612-620.
102. Chistiakov D.A., Sobenin I.A., Orekhov A.N. Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response. Immunol Lett 2013, 151:10-22.
103. Zhu J., Chen T., Yang L., et al. Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS One 2012, 7:e46551.
104. Foks A.C., Bot I., Frodermann V., et al. Interference of the CD30-CD30L pathway reduces atherosclerosis development. Arterioscler Thromb Vasc Biol 2012, 32:2862-2868.
105. Pinderski Oslund L.J., Hedrick C.C., Olvera T., et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999, 19:2847-2853.
106. Pinderski L.J., Fischbein M.P., Subbanagounder G., et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002, 90:1064-1071.
107. Xie G., Myint P.K., Zaman M.J., et al. Relationship of serum interleukin-10 and its genetic variations with ischemic stroke in a Chinese general population. PLoS One 2013, 8:e74126.
108. Mallat Z., Heymes C., Ohan J., Faggin E., Leseche G., Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999, 19:611-616.
109. Mallat Z., Besnard S., Duriez M., et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999, 85:e17-e24.
110. Nishihira K., Imamura T., Yamashita A., et al. Increased expression of interleukin-10 in unstable plaque obtained by directional coronary atherectomy. Eur Heart J 2006, 27:1685-1689.
111. Terkeltaub R.A. IL-10: an "immunologic scalpel" for atherosclerosis?. Arterioscler Thromb Vasc Biol 1999, 19:2823-2825.
112. McCarthy C., Duffy M.M., Mooney D., et al. IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis. FASEB J 2013, 27:499-510.
113. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., de Vries J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991, 174:1209-1220.
114. Peguet-Navarro J., Moulon C., Caux C., Dalbiez-Gauthier C., Banchereau J., Schmitt D. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur J Immunol 1994, 24:884-891.
115. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991, 147:3815-3822.
116. Almer G., Frascione D., Pali-Scholl I., et al. Interleukin-10: an anti-inflammatory marker to target atherosclerotic lesions via PEGylated liposomes. Mol Pharm 2013, 10:175-186.
117. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
118. Cardilo-Reis L., Gruber S., Schreier S.M., et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med 2012, 4:1072-1086.
119. Gallagher G., Eskdale J., Jordan W., et al. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol 2004, 4:615-626.
120. Gallagher G. Interleukin-19: multiple roles in immune regulation and disease. Cytokine Growth Factor Rev 2010, 21:345-352.
121. Tian Y., Sommerville L.J., Cuneo A., Kelemen S.E., Autieri M.V. Expression and suppressive effects of interleukin-19 on vascular smooth muscle cell pathophysiology and development of intimal hyperplasia. Am J Pathol 2008, 173:901-909.
122. Jain S., Gabunia K., Kelemen S.E., Panetti T.S., Autieri M.V. The anti-inflammatory cytokine interleukin 19 is expressed by and angiogenic for human endothelial cells. Arterioscler Thromb Vasc Biol 2011, 31:167-175.
123. Banchereau J., Pascual V., O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 2012, 13:925-931.
124. Rader D.J., Parmacek M.S. Secreted miRNAs suppress atherogenesis. Nat Cell Biol 2012, 14:233-235.
125. Mayr M., Zampetaki A., Willeit P., Willeit J., Kiechl S. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler Thromb Vasc Biol 2013, 33:206-214.